1
|
Whelan AR, Lambert-Messerlian GM, Kloza EM, Palomaki GE. First-trimester screening for pre-eclampsia: estimated vs measured mean arterial pressure. Ultrasound Obstet Gynecol 2022; 59:692-693. [PMID: 34985821 DOI: 10.1002/uog.24850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/23/2021] [Accepted: 12/29/2021] [Indexed: 06/14/2023]
Affiliation(s)
- A R Whelan
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Providence, RI, USA
| | - G M Lambert-Messerlian
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Providence, RI, USA
- Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Providence, RI, USA
- Department of Pathology and Laboratory Medicine, Alpert Medical School, Brown University, Providence, RI, USA
| | - E M Kloza
- Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Providence, RI, USA
| | - G E Palomaki
- Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Providence, RI, USA
- Department of Pathology and Laboratory Medicine, Alpert Medical School, Brown University, Providence, RI, USA
| |
Collapse
|
2
|
Oktay K, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN. Abstract PD6-06: Impact of BRCA mutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd6-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The BRCA1/2 genes are key members of the ataxia-telangiectasia mutated (ATM)-mediated DNA double strand break (DSB) repair pathway. Recent research showed that germline mutations in these genes result in DNA repair deficiency in oocytes, leading to accelerated ovarian aging as manifested by lower ovarian reserve and earlier age at natural menopause. Because we discovered that oocyte DNA repair is similarly critical in chemotherapy-induced ovarian follicle loss, we hypothesized that women with pathogenic mutations in BRCA1/2 genes may experience larger declines in ovarian reserve after chemotherapy. To gauge the degree of the chemotherapy-induced ovarian damage, we utilized serum anti-mullerian hormone (AMH), which is the most reliable current marker for assessing oocyte reserve.
Methods: Women with early stage breast cancer were enrolled before chemotherapy (Trial registration number: NCT00823654) between January 2009 and November 2017. Sera were obtained at baseline, before the initiation of treatment, and 18 to 24 months after the completion of chemotherapy. Stored sera were assayed at once for anti-mullerian hormone (AMH) and the results were adjusted for the women's age at sample collection. Of the 235 enrolled, 117 evaluable women were stratified into three groups, those never tested (based on NCCN Guidelines V 1.2018 ; n=38) and those negative (n=65) or positive (n=14) for a pathogenic BRCA mutation. Ovarian recovery was defined as the geometric mean of the post chemotherapy age-adjusted AMH levels compared to baseline.
Results: Compared to the lower risk (BRCA-untested) control group, AMH levels averaged 76% and 66% in those negative or positive for BRCA mutations (p=0.078). The geometric mean recoveries for the three groups (not tested, BRCA negative and BRCA positive) were 3.7%, 5.2% and 1.6%, respectively. The mean recovery in the BRCA mutation positive group was about one-third the 4.6% recovery in the other two groups combined (two group ANOVA, p=0.034, F=4.89). Given the potential of the ovarian recovery to be dependent on type of chemotherapy, the data were reanalyzed for all three BRCA groups after restriction to those treated with the AC-T (doxorubicin and cyclophosphamide followed by paclitaxel) regimen. Of the 108 women in the previous analysis, 83 (77%) were treated with AC-T; 25, 46 and 12 women in the three groups, respectively. The geometric mean AMH recoveries for these new groups were 3.2%, 4.7% and 1.3%. When the BRCA mutation positive group was compared with other two groups, the former had significantly worse recovery of serum AMH levels (ANOVA, p=0.044, F=4.2).
Conclusions: These data show that women with breast cancer and pathogenic BRCA mutations have striking liability to chemotherapy-induced ovarian reserve loss and may have to be preferentially counselled on fertility preservation methods. In addition, taken together with the previous data showing that women with BRCA mutations may have accelerated ovarian aging, even unaffected reproductive age individuals may have to be proactive about family building or early preservation of their fertility (Supported by NIH R01HD053112).
Citation Format: Oktay K, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN. Impact of BRCA mutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD6-06.
Collapse
Affiliation(s)
- K Oktay
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - G Bedoschi
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - SB Goldfarb
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - E Taylan
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - S Titus
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - GE Palomaki
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - T Cigler
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - M Robson
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| | - MN Dickler
- Yale University School of Medicine, New Haven; Memorial Sloan Kettering Cancer Center, New York; Women & Infants Hospital and Alpert Medical School at Brown University, Providence; Weill Medical College of Cornell University, New York
| |
Collapse
|
3
|
Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. J Med Screen 2016; 8:2-7. [PMID: 11373844 DOI: 10.1136/jms.8.1.2] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Objective To compare the Down's syndrome screening performance of a simplified dimeric inhibin-A assay (Diagnostic Systems Laboratories (DSL)) with an assay whose clinical utility has been established (Serotec). Setting A case control set consisting of 51 Down's syndrome and 245 matched unaffected pregnancies collected as part of an earlier multicentre cohort study. Methods Sera were assayed for dimeric inhibin-A using the DSL assay and Serotec reference assay. Data analysis included a method comparison of mass values, fit of data to a logarithmic Gaussian distribution, and determination of detection and false positive rates. In addition, 234 fresh sera were assayed using the simplified method. Results The two assays showed a high correlation (r =0.93) but average concentrations of the DSL assay were 48% higher. However, the differences were basically proportional over the range of values important for screening. The detection rate was essentially equivalent for the DSL assay whether analysed univariately or in combination with other markers (for example, 79% v 75% at a 5% false positive rate for the DSL and Serotec assays for the combination of α fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, and dimeric inhibin-A, respectively). The 234 dimeric inhibin-A values measured on fresh sera fitted a logarithm Gaussian distribution for the DSL assay, as indicated by the fit to a probability plot. Conclusions The Down's syndrome screening performance of a simplified dimeric inhibin-A immunoassay was equivalent to a more labour intensive established dimeric inhibin-A assay.
Collapse
Affiliation(s)
- G J Knight
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA.
| | | | | | | | | |
Collapse
|
4
|
Palomaki GE, Kloza EM, Lambert-Messerlian GM, van den Boom D, Ehrich M, Deciu C, Bombard AT, Haddow JE. Circulating cell free DNA testing: are some test failures informative? Prenat Diagn 2015; 35:289-93. [DOI: 10.1002/pd.4541] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Revised: 11/25/2014] [Accepted: 11/26/2014] [Indexed: 12/26/2022]
Affiliation(s)
- G. E. Palomaki
- Department of Pathology and Laboratory Medicine; Women & Infants Hospital; Providence RI USA
- Alpert Medical School; Brown University; Providence RI USA
- Savjani Institute for Health Research; Windham ME USA
| | - E. M. Kloza
- Department of Pathology and Laboratory Medicine; Women & Infants Hospital; Providence RI USA
- Savjani Institute for Health Research; Windham ME USA
| | - G. M. Lambert-Messerlian
- Department of Pathology and Laboratory Medicine; Women & Infants Hospital; Providence RI USA
- Alpert Medical School; Brown University; Providence RI USA
| | | | | | - C. Deciu
- Sequenom Biosciences; San Diego CA USA
| | - A. T. Bombard
- Sequenom, Inc; San Diego CA USA
- Sequenom Biosciences; San Diego CA USA
- ATB: Progenity, Inc.; San Diego CA USA
| | - J. E. Haddow
- Department of Pathology and Laboratory Medicine; Women & Infants Hospital; Providence RI USA
- Alpert Medical School; Brown University; Providence RI USA
- Savjani Institute for Health Research; Windham ME USA
| |
Collapse
|
5
|
Palomaki GE, Ashwood ER, Weck KE. A flawed challenge but valid recommendation: a response to Takoudes and Hamar. Ultrasound Obstet Gynecol 2015; 45:117. [PMID: 25557844 DOI: 10.1002/uog.14739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- G E Palomaki
- Department of Pathology and Laboratory Medicine, Women & Infants Hospital/Alpert Medical School at Brown University, Providence, RI, USA
| | | | | |
Collapse
|
6
|
|
7
|
Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ. The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. J Med Screen 2005; 11:170-4. [PMID: 15563772 DOI: 10.1258/0969141042467340] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE To further explore first and second trimester reference ranges for thyroid stimulating hormone (TSH) and examine within-person variability of TSH and thyroid peroxidase (TPO) antibody. SETTING Women coming for routine prenatal care in early pregnancy agreed to participate in a trial of integrated serum screening for Down's syndrome. Two serum samples were obtained from each woman, one each in the first and second trimesters. These samples were also available for TSH and TPO measurements in the present study. METHODS TSH and TPO antibody measurements were performed in 1126 women with ultrasound-dated pregnancies who provided serum samples in both trimesters. TSH reference ranges were established for the entire cohort and for the antibody-negative subgroup. Within-person variability of TSH measurements between trimesters was examined. RESULTS Median TSH values are lower in the first trimester than in the second (1.00 versus 1.29 mIU/l), but 98th centile values are higher (5.20 versus 4.18 mIU/l). High correlation exists between individual women's first and second trimester TSH measurements (r=0.75, r2=0.56, p<0.001). Among 23 women with TSH values above the 98th centile in the second trimester, 17 (74%) were over the 95th centile in the first trimester. TPO antibody measurements are also highly correlated between trimesters (r=0.97, r)=0.94). CONCLUSION Proper interpretation of TSH measurements during pregnancy requires that laboratories establish and monitor appropriate reference ranges. TSH levels show high within-person consistency between trimesters.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, Maine 04070, USA.
| | | | | | | | | |
Collapse
|
8
|
Palomaki GE, Williams J, Haddow JE. Comparing the observed and predicted effectiveness of folic acid fortification in preventing neural tube defects. J Med Screen 2004; 10:52-3. [PMID: 12790316 DOI: 10.1258/096914103321610815] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
9
|
Haddow JE, Palomaki GE, McClain M, Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 2004; 10:11-3. [PMID: 12790309 DOI: 10.1258/096914103321610743] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVES Homozygosity for the C282Y mutation of the HFE gene is the main cause of iron overload in hereditary haemochromatosis. This study calculated the number of hepatocellular carcinoma cases among a cohort of white males that could be attributed to C282Y homozygosity. A better understanding of the extent of potentially preventable mortality arising from this cancer might help with decision making about the feasibility of population screening. METHODS We combined information from published life tables, age-specific cancer rates and DNA studies of archived liver biopsy specimens to calculate the number of cases of hepatocellular carcinoma that might occur during the lifetime of a cohort of 1,000,000 men, including a subgroup of 5000 C282Y homozygotes. RESULTS Hepatocellular carcinoma was estimated to occur in 2673 men in the cohort (1:374); 267 of these cases were in the subgroup of 5000 C282Y homozygotes (1:17). If these 267 cases were prevented, the remaining lifetime risk among all males would be 1:416. The relative risk for this cancer in C282Y homozygotes is 23. CONCLUSIONS There continues to be uncertainty about the efficacy of screening for haemochromatosis. Hepatocellular carcinoma is the most readily quantifiable serious health problem attributable to this source. Further confirmatory DNA (C282Y) studies would be helpful in larger, unbiased sets of archived biopsy specimens, as a way to confirm the present estimate. Any strategy designed to prevent attributable liver cancer is likely to prevent other serious problems from haemochromatasis as well.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, 69 US Route One, Scarborough, Maine 04074, USA.
| | | | | | | |
Collapse
|
10
|
Abstract
Cystic fibrosis is a serious disorder. Research into the treatment of affected individuals is in progress, but a cure is not expected in the near future. In this review, we demonstrate that prenatal screening for cystic fibrosis meets the requirements for a worthwhile screening programme. We explain the reasons that have led us to conclude that one approach ('couple screening') is the method of choice. The couple-based approach calls for reporting results to the couple as a unit. Only if both parents are found to be carriers is the result designated screen-positive and an amniocentesis or chorionic villus sampling offered. This offers a substantial reduction in the proportion of women with unaffected pregnancies with positive results (the false-positive rate) compared with other methods without reducing the detection of affected pregnancies. It also avoids creating a screen-positive group for which no definitive diagnosis is available. This is a problem with other screening methods. The couple method can achieve a 72% detection rate for a 0.1% false-positive rate. The screening method is simple, non-invasive, reliable, safe and reasonably cost effective. Existing programmes have shown that screening using this method is acceptable to health care professionals and patients. Setting up a national prenatal screening programme for cystic fibrosis is timely and should be implemented using the couple screening method.
Collapse
Affiliation(s)
- N J Wald
- Wolfson Institute of Preventive Medicine, Barts and the London Queen Mary School of Medicine and Dentistry, London, UK.
| | | | | | | | | |
Collapse
|
11
|
Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE. Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. J Med Screen 2002; 9:43-4. [PMID: 11943798 DOI: 10.1136/jms.9.1.43] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To design a reliable model in the context of prenatal screening for assigning the risk in an individual pregnancy of Smith-Lemli-Opitz syndrome (SLOS) and assess its performance. SETTING A 2nd trimester screening programme for Down's syndrome that measures unconjugated estriol (uE3) along with other serum markers. METHODS Development of individual risk estimates with a trivariate model incorporating measurements of maternal serum uE3, alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG) in both SLOS and unaffected pregnancies. RESULTS Population parameters were computed for the three analytes, as were pairwise correlation coefficients and truncation limits, based on an unbiased collection of 29 affected pregnancies. Published parameters were used for unaffected pregnancies. With a cut off level of risk of 1:50, 62% of SLOS pregnancies can be detected by initially identifying 0.34% of unaffected pregnancies as screen positive. About 1 in 90 screen positive pregnancies will be affected. CONCLUSIONS It is possible to screen for SLOS as an add on to existing 2nd trimester maternal serum screening, if uE3 is already being measured. A large, prospective trial is necessary to determine whether diagnostic testing can be performed in maternal urine or serum rather than amniotic fluid.
Collapse
Affiliation(s)
- G E Palomaki
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA.
| | | | | | | | | |
Collapse
|
12
|
Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE. Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. J Med Screen 2002; 8:173-7. [PMID: 11743032 DOI: 10.1136/jms.8.4.173] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To evaluate two hypothetical screening strategies for identifying children with long QT syndrome (LQTS), a cause of sudden death in childhood. METHODS Families with KVLQT1, HERG, or SCN5A genotypes provided electrocardiographic (ECG) data for this analysis. This is the first time such genotype-phenotype information has been available. Using the LQTS genotype, the distributions of QTc in affected and unaffected children were established and screening performance for various QTc cut off points were modelled. The detection rate for DNA mutation analysis was determined from published experience. RESULTS The mean QTc (SD) was 0.484 seconds (0.031) in 117 affected children and 0.420 seconds (0.021) in 133 unaffected children. A QTc cut off of 0.50 seconds in a population of 1 million children would identify 61 of the 200 affected children, and 100 unaffected children. Estimates of testing costs for a screening programme in the newborn period would be $327 869/case detected and $2 222 000/death avoided. Although not presently available for routine use, DNA analysis could, theoretically, identify 100 of the 200 children with LQTS within the same population, along with an estimated 100 unaffected children. CONCLUSION The only available screening test for LQTS is ECG measurement. If DNA technology becomes available for screening, unit costs must be very low to be competitive. There are multiple problems with screening for LQTS: only a minority of children will be detected, cost/death avoided is high, and pilot studies would need to be in place for 5-10 years to document efficacy.
Collapse
Affiliation(s)
- W C Allan
- Foundation for Blood Research, PO Box 190, 69 US Route One, Scargborough, ME 04070-0190, USA.
| | | | | | | | | | | |
Collapse
|
13
|
Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE. Long QT syndrome in children: the value of the rate corrected QT interval in children who present with fainting. J Med Screen 2002; 8:178-82. [PMID: 11743033 DOI: 10.1136/jms.8.4.178] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE A strategy was evaluated for identifying a proportion of children with long QT syndrome (LQTS) using the rate corrected QT interval (QTc) to systematically evaluate children who faint. METHODS QTc measurements and rates of fainting for the present analysis are available from families with KVLQT1, HERG, or SCN5A genotypes. QTc distributions in affected and unaffected children were documented and detection and false positive rates were modelled. RESULTS The mean QTc (SD) in 117 affected children was 0.484 seconds (0.031), and 0.420 seconds (0.021) among 133 unaffected children. At a cut off of 0.49 seconds, QTc measurement will identify 42.5% of affected and 0.1% of unaffected persons with a history of fainting who are alive at the time of testing. Assumptions include a prevalence of 1:5000 for LQTS, 2% mortality with the first arrhythmia, and a rate of fainting of 50% in affected children and 7% in unaffected children. Given these variables, a QTc cut off of 0.49 seconds detects 42 of 200 affected, along with 70 unaffected children out of a population of 1 million. If QTc > or = 0.49 seconds is found in either parent of children with a QTc of 0.44 through 0.48 seconds, another 21 affected and 25 unaffected children will be identified. CONCLUSION Systematically performing QTc measurements as part of the evaluation of children who faint might optimally identify about one third of patients with LQTS with few false positives and thereby offer an opportunity to prevent some sudden deaths.
Collapse
Affiliation(s)
- W C Allan
- Foundation for Blood Research, PO Box 190, 69 US Route One, Scarborough, ME 04070-0190, USA.
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
Quantification of serum proteins is useful in the diagnosis and clinical management of many disorders. With the introduction of automated analyzers and standardized reference materials, one of the last barriers to more widespread utilization of these measurements is the lack of availability of reliable and transferable age- and gender-specific reference ranges. One normalization method that deserves consideration is converting values to multiples of the median (MoM) for age and gender. When two analytic methods agree, or differ only by a proportional amount, conversion to MoM can be used to simplify the clinical interpretation of serum protein results. As a test of this method, assay results for IgG, transferrin, and albumin from three Swedish hospitals were normalized using published reference ranges from the United States. All assays were standardized to CRM 470. IgG results were in agreement in mass units, and transferrin measurements were proportionally different. However, there were important, non-proportional differences in albumin measurements. After converting IgG and transferrin measurements to MoM, published reference ranges were appropriate for the Swedish Hospitals.
Collapse
Affiliation(s)
- G E Palomaki
- Foundation for Blood Research, Scarborough, Maine 04038, USA.
| | | |
Collapse
|
15
|
Steele BW, Wang E, Palomaki GE, Klee GG, Elin RJ, Soldin SJ, Witte DL. An evaluation of analytic goals for assays of drugs: a College of American Pathologists Therapeutic Drug Monitoring Survey Study. Arch Pathol Lab Med 2001; 125:729-35. [PMID: 11371222 DOI: 10.5858/2001-125-0729-aeoagf] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To determine if the levels of imprecision of the commonly used analytic methods for drug measurements are suitable for long-term therapeutic drug monitoring. DESIGN In 1996, 4 identical lyophilized samples (2 in the first mailing and 2 in the second mailing 4 months later) were sent to laboratories participating in a nationwide proficiency testing program. Similarly, in 1999, replicates from a liquid pool of spiked sera were mailed 3 times, 4 months apart, to participating laboratories. For each of 11 drugs regulated under the Clinical Laboratory Improvement Amendments of 1988 and 1 metabolite, the total variance for each method was partitioned into within- and between-laboratory components. The total within-laboratory and the total survey coefficients of variation (CVs) for each method were then compared with the "acceptable" precision criteria of Glick, Burnett, and Fraser for each drug. SETTING The first 2 mailings of the College of American Pathologists Therapeutic Drug Monitoring surveys for 1996, sets Z and ZM, and the 3 mailings of 1999, sets ZM, Z, and Z2. MAIN OUTCOME MEASURES For each drug studied, the CV of each method was compared with the various imprecision criteria, and if greater than any of the criteria, the method was then tabulated as not meeting that specific criterion.Participants.-The approximately 5000 participants of the survey. RESULTS The number of methods deemed as not having acceptable total long-term within-laboratory precision by the various criteria ranged from 35% to 88% in 1996 and from 22% to 77% in 1999. CONCLUSION The number of failures possibly indicates that many of the reagent assays being utilized are not precise enough for long-term therapeutic drug monitoring of chronically administered drugs or that the published criteria used to evaluate the data in this study are too stringent.
Collapse
Affiliation(s)
- B W Steele
- Department of Pathology, University of Miami School of Medicine, Miami, FL, USA.
| | | | | | | | | | | | | |
Collapse
|
16
|
Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, Faix JD, Klein RZ. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2001; 7:127-30. [PMID: 11126160 DOI: 10.1136/jms.7.3.127] [Citation(s) in RCA: 339] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To examine the relation between certain pregnancy complications and thyroid stimulating hormone (TSH) measurements in a cohort of pregnant women. METHODS TSH was measured in sera obtained from women during the second trimester as part of routine prenatal care. Information was then collected about vaginal bleeding, premature delivery, low birthweight, abruptio placentae, pregnancy induced hypertension, need for cesarean section, low Apgar scores, and fetal and neonatal death. RESULTS Among 9403 women with singleton pregnancies, TSH measurements were 6 mU/l or greater in 209 (2.2%). The rate of fetal death was significantly higher in those pregnancies (3.8%) than in the women with TSH less than 6 mU/l (0.9%, odds ratio 4.4, 95% confidence interval 1.9-9.5). Other pregnancy complications did not occur more frequently. CONCLUSION From the second trimester onward, the major adverse obstetrical outcome associated with raised TSH in the general population is an increased rate of fetal death. If thyroid replacement treatment avoided this problem this would be another reason to consider population screening.
Collapse
Affiliation(s)
- W C Allan
- Foundation for Blood Research, Scarborough, Maine, USA.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Mitchell ML, Hermos RJ, Larson CA, Palomaki GE, Haddow JE. Prevalence of GAD autoantibodies in women with gestational diabetes: a retrospective analysis. Diabetes Care 2000; 23:1705-6. [PMID: 11092299 DOI: 10.2337/diacare.23.11.1705] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
18
|
Affiliation(s)
- JE Haddow
- Foundation for Blood Research, Scarborough, Maine, USA
| | | | | |
Collapse
|
19
|
Abstract
Inhibin A is effective as a second trimester maternal serum marker for Down syndrome screening. In the present study, inhibin A levels were measured in second trimester maternal serum samples from 28 pregnancies affected with open neural tube defects; 12 associated with open spina bifida and 16 associated with anencephaly. Each measurement was expressed as a multiple of the median (MoM) for control singleton pregnancies (n=1464) of the same completed week of gestation. Inhibin A levels were not significantly altered in cases of open neural tube defects; the median value was 0.96 MoM in cases of open spina bifida and 1.19 MoM in cases of anencephaly. Therefore, second trimester maternal serum inhibin A levels will not have an impact on prenatal detection of open neural tube defects.
Collapse
Affiliation(s)
- G M Lambert-Messerlian
- Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Brown University School of Medicine, Providence, Rhode Island, Scarborough, Maine, USA.
| | | | | |
Collapse
|
20
|
Saller DN, Canick JA, Blitzer MG, Palomaki GE, Schwartz S, Blakemore KJ, Haddow JE. Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999; 19:813-6. [PMID: 10521837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The aim of this study was to determine whether pregnancies affected by fetal trisomy 13 are associated with second-trimester maternal serum analyte levels different from those typical of the unaffected population. Pregnancies with trisomy 13 were identified through cytogenetics laboratories. Those which had second-trimester maternal serum screening analyte measurements were further evaluated. Maternal serum analyte levels for each case and five matched controls were statistically analysed by matched ranked-sum analysis. 28 cases of fetal trisomy 13 were identified. The median AFP, uE3 and hCG levels were 1.35 MoM, 0.71 MoM and 0.90 MoM, respectively. Only uE3 levels were statistically different (p < 0.01) from those for the unaffected population. These data suggest that second-trimester maternal serum AFP, uE3 and hCG levels are not useful in detecting fetal trisomy 13 and protocols already existing for Down syndrome or trisomy 18 screening will not detect the majority of cases of this aneuploidy.
Collapse
Affiliation(s)
- D N Saller
- Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, NY, USA
| | | | | | | | | | | | | |
Collapse
|
21
|
Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341:549-55. [PMID: 10451459 DOI: 10.1056/nejm199908193410801] [Citation(s) in RCA: 1390] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND When thyroid deficiency occurs simultaneously in a pregnant woman and her fetus, the child's neuropsychological development is adversely affected. Whether developmental problems occur when only the mother has hypothyroidism during pregnancy is not known. METHODS In 1996 and 1997, we measured thyrotropin in stored serum samples collected from 25,216 pregnant women between January 1987 and March 1990. We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percentile of the values for all the pregnant women, 15 women with values between the 98th and 99.6th percentiles, inclusive, in combination with low thyroxine levels, and 124 matched women with normal values. Their seven-to-nine-year-old children, none of whom had hypothyroidism as newborns, underwent 15 tests relating to intelligence, attention, language, reading ability, school performance, and visual-motor performance. RESULTS The children of the 62 women with high serum thyrotropin concentrations performed slightly less well on all 15 tests. Their full-scale IQ scores on the Wechsler Intelligence Scale for Children, third edition, averaged 4 points lower than those of the children of the 124 matched control women (P= 0.06); 15 percent had scores of 85 or less, as compared with 5 percent of the matched control children. Of the 62 women with thyroid deficiency, 48 were not treated for the condition during the pregnancy under study. The full-scale IQ scores of their children averaged 7 points lower than those of the 124 matched control children (P=0.005); 19 percent had scores of 85 or less. Eleven years after the pregnancy under study, 64 percent of the untreated women and 4 percent of the matched control women had confirmed hypothyroidism. CONCLUSIONS Undiagnosed hypothyroidism in pregnant women may adversely affect their fetuses; therefore, screening for thyroid deficiency during pregnancy may be warranted.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, ME 04074, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
OBJECTIVE To summarise a conference convened to examine how cystic fibrosis screening might appropriately be introduced into routine prenatal practice. METHODS Participants included experts from various relevant disciplines. Systematic reviews and data from individual trials were presented; issues were identified and discussed. RESULTS Judged by published criteria, prenatal cystic fibrosis screening is suitable for introduction. Screening can be performed cost effectively by identifying racial/ethnic groups at sufficient risk and then using either of two models for delivering laboratory services. Validated educational materials exist. Ethical issues are not unique. CONCLUSIONS Once adequate facilities for patient and provider education, testing, counselling, quality control, and monitoring are in place, individual programmes can begin prenatal screening for cystic fibrosis.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA
| | | | | | | |
Collapse
|
23
|
|
24
|
Haddow JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJ, Cheuvront B, Cunningham GC, Donnenfeld AE, Erickson JL, Erlich HA, Ferrie RM, FitzSimmons SC, Greene MF, Grody WW, Haddow PK, Harris H, Holmes LB, Howell RR, Katz M, Klinger KW, Kloza EM, LeFevre ML, Little S, Loeben G, McGovern M, Pyeritz RE, Rowley PT, Saiki RK, Short MP, Tabone J, Wald NJ, Wilker NL, Witt DR. Issues in implementing prenatal screening for cystic fibrosis: results of a working conference. Genet Med 1999; 1:129-35. [PMID: 11258347 DOI: 10.1097/00125817-199905000-00003] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
PURPOSE To summarize a conference convened to examine how cystic fibrosis screening might appropriately be introduced into routine prenatal practice. METHODS Participants included experts from various relevant disciplines. Systematic reviews and data from individual trials were presented; issues were identified and discussed. RESULTS Judged by published criteria, prenatal cystic fibrosis screening is suitable for introduction. Screening can be performed cost-effectively by identifying racial/ethnic groups at sufficient risk and then using either of two models for delivering laboratory services. Validated educational materials exist. Ethical issues are not unique. CONCLUSIONS Once adequate facilities for patient and provider education, testing, counseling, quality control, and monitoring are in place, individual programs can begin prenatal screening for cystic fibrosis.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
|
26
|
Bradley LA, Palomaki GE, Knight GJ, Haddow JE, Opitz JM, Irons M, Kelley RI, Tint GS. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. Am J Med Genet 1999; 82:355-8. [PMID: 10051173 DOI: 10.1002/(sici)1096-8628(19990212)82:4<355::aid-ajmg16>3.0.co;2-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
27
|
Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J Clin Lab Anal 1999; 13:280-6. [PMID: 10633295 PMCID: PMC6807761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/1999] [Accepted: 07/20/1999] [Indexed: 02/15/2023] Open
Abstract
Clinical interpretation of the acute-phase proteins--albumin, transferrin, and transthyretin--has been hampered by the lack of accurate and precise methods for quantifying the levels and a stable and respected reference material. Now that these issues have been addressed, the community is faced with the need for credible age- and gender-specific reference values. The number of publications that address this issue, even for an analyte as familiar as albumin, is small and, in most cases, such publications lack the relevant data that would allow a combined experience to be created. We have identified 40 studies that meet our criteria: a description of the study participants' health status, of the statistical methodology, and of the laboratory technique and/or reference material used. Few of these studies reported values stratified by gender. A summary of the published median levels by age is presented for the three analytes, along with our own age- and gender-specific medians based on a large cohort. Ten of the studies presented a 95 percent reference range, in close agreement with ours where selection was based upon reported diagnosis rather than upon determination of individual health status. This meta-analysis provides support for the reliability of our recently published methodology and reference data for the clinical interpretation of individual albumin, transferrin, and transthyretin values. As with most laboratory measurements, clinical interpretation requires that other laboratory and clinical factors be considered.
Collapse
Affiliation(s)
- R F Ritchie
- Foundation for Blood Research, Scarborough, Maine 04074, USA.
| | | | | | | |
Collapse
|
28
|
Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999; 13:273-9. [PMID: 10633294 PMCID: PMC6808097 DOI: 10.1002/(sici)1098-2825(1999)13:6<273::aid-jcla4>3.0.co;2-x] [Citation(s) in RCA: 185] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/1999] [Accepted: 07/20/1999] [Indexed: 12/31/2022] Open
Abstract
Inflammation is associated with diverse clinical conditions accompanied by characteristic changes in serum levels of the acute-phase proteins that can be used to stage the inflammatory process and evaluate the impact of treatment. Some acute-phase proteins increase during inflammation, while others, such as albumin, transferrin, and transthyretin, decrease. The current study reports reference ranges for serum levels of albumin, transferrin, and transthyretin based on a cohort of over 124,000 Caucasian individuals from northern New England, tested in our laboratory between 1986 and 1998. Measurements were standardized against CRM 470 (RPPHS) and analyzed using a previously validated statistical approach. Individuals with laboratory evidence of inflammation (C-reactive protein of 10 mg/L or higher) were excluded. The levels of all three analytes varied by age, generally rising until the second or third decade of life and then decreasing thereafter. Albumin and transthyretin levels were higher during midlife among males as compared to females; the maximum being at 25 years for albumin (5%) and 35 years for transthyretin (16%). In contrast, above the age of 10 years, transferrin levels were increasingly higher among females (7% at 20 years). When values were expressed as multiples of the age- and gender-specific median levels, the resulting distributions fitted a log-Gaussian distribution. When patient data are normalized in this manner, the distribution parameters can be used to assign a corresponding centile to an individual's measurement simplifying interpretation. The ultimate interpretation of an individual's measurement relies upon the clinical setting.
Collapse
Affiliation(s)
- R F Ritchie
- Foundation for Blood Research, Scarborough, Maine 04074, USA.
| | | | | | | | | | | |
Collapse
|
29
|
Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44:2301-6. [PMID: 9799757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Although in vitro studies support a pathophysiologic role for lipoprotein(a) [Lp(a)] in the development of atherosclerosis, and retrospective studies consistently report that there is a relationship between Lp(a) and ischemic heart disease (IHD), the conclusions drawn from prospective studies about this relationship have been inconsistent. To address this issue, we have performed a metaanalysis of data available from prospective studies. Lp(a) concentrations expressed as mass units vary markedly between studies, reflecting the need for assay standardization. In 12 of 14 prospective studies, Lp(a) concentrations are higher in subjects who later develop IHD (cases) than in those who do not (controls), although there is variation in the size of the effect. Sample storage temperature may contribute to this variability. When the studies are analyzed collectively, Lp(a) concentrations are significantly higher in cases than in controls, and the extent of the effect is similar in men and women. These findings provide evidence in support of a causal role for Lp(a) in the development of atherosclerosis. Measurement of Lp(a) may be useful to guide management of individuals with a family history of IHD or with existing disease. The separation in values between cases and controls is not, however, sufficient to allow the use of Lp(a) as a screening test in the general population.
Collapse
Affiliation(s)
- W Y Craig
- Foundation for Blood Research, Scarborough, ME 04070-0190, USA.
| | | | | | | | | |
Collapse
|
30
|
Abstract
OBJECTIVES To determine the second trimester Down's syndrome screening performance of maternal serum dimeric inhibin A, both alone and in combination with existing serum markers. SETTING A case-control set of serum samples from patients with Down's syndrome (52) and subjects with matched unaffected pregnancies obtained in a previous cohort study before second trimester amniocentesis and karyotyping. The amniocenteses were performed for reasons other than a positive serum screening test result. METHODS For each serum from a Down's syndrome pregnancy, five serum samples from pregnancies with a normal karyotype were matched for recruitment centre, gestational age, maternal age, and date of amniocentesis. A specific form of inhibin (dimeric inhibin A) was measured using monoclonal antibodies. Measurements of alpha fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin and its free beta subunit were already available. Screening performance was modelled using distribution variables of the analytes coupled with the 1993 age distribution of pregnant women in the United States. RESULTS The median dimeric inhibin A level was 2.10 times higher in Down's syndrome pregnancies. When dimeric inhibin A was combined with maternal age and three other serum markers (alpha fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin) the Down's syndrome detection rate increased to 75% (from 66%) at a 5% false positive rate. If dimeric inhibin A could be added for less than $31 (ranging from $16 to $39 depending on the detection rate, markers chosen, and method of dating), the cost of detecting each Down's syndrome pregnancy and the number of procedure related fetal losses would both be reduced. CONCLUSIONS The addition of dimeric inhibin A to prenatal screening programmes for Down's syndrome should be considered, or possibly it could be substituted for an existing serum marker. One barrier to implementation in the United States, however, is the unavailability of kits with Food and Drug Administration approval.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, ME 04074, USA
| | | | | | | | | |
Collapse
|
31
|
Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, Ferrie RM. Hereditary haemochromatosis mutation frequencies in the general population. J Med Screen 1998; 5:34-6. [PMID: 9575458 DOI: 10.1136/jms.5.1.34] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVES This study aims to expand our knowledge of the general population frequency of two mutations, C282Y and H63D, identified in the candidate gene for hereditary haemochromatosis, and to determine whether the testing can be performed using routinely obtained cheek-brush (buccal) samples. SETTING Banked buccal lysate samples, randomised and coded for anonymity, from a cohort of couples who underwent prenatal cystic fibrosis screening in Maine. METHODS A multiplex ARMS test was performed on buccal cell lysates to identify the two mutations. RESULTS Genotype frequencies found among the 1001 subjects studied (502 women, 499 men) were: seven C282Y homozygotes, 22 C282Y/H63D compound heterozygotes, 97 C282Y heterozygotes, 17 H63D homozygotes, 246 H63D heterozygotes, and 612 individuals with no detectable mutation. The allele frequencies for C282Y and H63D were 0.066 and 0.151, respectively. CONCLUSIONS Observed genotype frequencies in Maine are consistent with expectations and with consensus data from five smaller studies. Combined mutational analysis data indicate that homozygosity for C282Y (the genotype found in about 85% of subjects with diagnosed hereditary haemochromatosis) occurs in 51 per 10,000 white subjects of northern European heritage; the corresponding total hereditary haemochromatosis prevalence of about 60 per 10,000 is consistent with previous estimates. The study also confirms that H63D would not be useful in general population screening for hereditary haemochromatosis.
Collapse
Affiliation(s)
- L A Bradley
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA
| | | | | | | | | | | |
Collapse
|
32
|
Haddow JE, Palomaki GE, Bradley LA, Doherty RA. Screening for cystic fibrosis. JAMA 1998; 279:1068; author reply 1069. [PMID: 9546561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
33
|
Abstract
BACKGROUND Screening of maternal serum to identify fetuses with Down's syndrome is now routinely offered during the second trimester of pregnancy. Prenatal screening by means of serum assays or ultrasonographic measurements, either alone or in combination, may also be possible in the first trimester. METHODS We measured serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin (hCG), the free beta subunit of hCG, and pregnancy-associated protein A in 4412 women (82 percent of whom were 35 years of age or older) who came to 16 prenatal diagnostic centers for chorionic-villus sampling or early amniocentesis at 9 to 15 weeks of gestation. Ultrasound measurements of fetal nuchal translucency were also reported. Fetal chromosomal analysis was performed in all pregnancies. Altogether, there were 61 fetuses with Down's syndrome. RESULTS A total of 48 pregnancies affected by Down's syndrome and 3169 unaffected pregnancies were identified before 14 weeks of gestation; the rates of detection of Down's syndrome for the five serum markers were as follows: 17 percent for alpha-fetoprotein, 4 percent for unconjugated estriol, 29 percent for hCG, 25 percent for the free beta subunit of hCG, and 42 percent for pregnancy-associated protein A, at false positive rates of 5 percent. The results of the measurements of serum hCG and its free beta subunit were highly correlated. When used in combination with the serum concentration of pregnancy-associated protein A and maternal age, the detection rate was 63 percent for hCG (95 percent confidence interval, 47 to 76 percent) and 60 percent for its free beta subunit (95 percent confidence interval, 45 to 74 percent). Measurements of nuchal translucency varied considerably between centers and could not be reliably incorporated into our calculations. CONCLUSIONS Screening for Down's syndrome in the first trimester is feasible, with use of measurements of pregnancy-associated protein A and either hCG or its free beta subunit in maternal serum.
Collapse
Affiliation(s)
- J E Haddow
- Foundation for Blood Research, Scarborough, ME 04070-0190, USA
| | | | | | | | | | | |
Collapse
|
34
|
Palomaki GE, Neveux LM, Haddow JE. Current Down syndrome risk estimates are reliable. Am J Obstet Gynecol 1998; 178:871-2. [PMID: 9579462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
35
|
Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free beta-subunit as screening tests for Down syndrome. Prenat Diagn 1998; 18:235-45. [PMID: 9556040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Published studies have reached varying conclusions as to the benefit of replacing human chorionic gonadotropin (hCG) measurements with the free beta-subunit of hCG (the free beta-subunit) for Down syndrome screening. One study reports 14 per cent higher detection for the free beta-subunit, while another finds an actual loss in detection. To explore this issue further, we directly compared the screening performance of hCG and the free beta-subunit, alone and in combination with other serum markers, using banked sera obtained prior to amniocentesis and karyotyping. Altogether, 52 Down syndrome and 5065 unaffected pregnancies were studied. Sera were thawed and assayed for hCG and the free beta-subunit over 1 year. At a 5 per cent false-positive rate, the detection rate for hCG in combination with maternal age and alpha-fetoprotein was higher than when the free beta-subunit was substituted (62 versus 57 per cent). Ultrasound dating and adding unconjugated oestriol both increased detection. The present findings, along with those from six case control studies (our re-analysis), indicate that the screening performances of hCG and the free beta-subunit are similar (median change in detection 0, range -8 to +3 per cent). Under optimal sample collection and transportation conditions, laboratories can expect to achieve similar screening performance using either hCG or the free beta-subunit measurements.
Collapse
Affiliation(s)
- G J Knight
- Foundation for Blood Research, Scarborough, Maine 04070-0190, USA
| | | | | | | | | |
Collapse
|
36
|
Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 1998; 12:363-70. [PMID: 9850188 PMCID: PMC6808031 DOI: 10.1002/(sici)1098-2825(1998)12:6<363::aid-jcla6>3.0.co;2-x] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/1998] [Accepted: 07/23/1998] [Indexed: 11/07/2022] Open
Abstract
Serum immunoglobulins are measured millions of times each year, yet clinical interpretations remain hampered by inadequate age- and gender-specific reference limits. In order to provide more reliable and comprehensive reference distributions for IgA, IgG, and IgM measurements, we analyzed automated immunoassay values from 115,017 serum samples from northern New England patients (99% Caucasian) who were tested in our laboratory between 1986 and 1995. Measurements were standardized to reference material, CRM 470 (RPPHS). A simple, practical, and clinically relevant approach was used to determine reference distributions for the immunoglobulins over a wide range of ages for males and females. Levels of IgA and IgM varied considerably by age, and by gender for IgM. For each of the analytes, the observed 5th and 95th centiles were symmetric about the median and approximately constant over the entire age range. When immunoglobulin reference values are expressed as multiples of the age- and gender-specific regressed medians, the resulting distributions fit a log-Gaussian distribution well. This finding enables interpretation of serum immunoglobulin measurements using a common unit (multiples of the median) that is independent of age or gender. Insights gained from this study can help improve and simplify the interpretation of immunoglobulin measurements.
Collapse
Affiliation(s)
- R F Ritchie
- Foundation for Blood Research, Scarborough, Maine 04074, USA.
| | | | | | | | | | | |
Collapse
|
37
|
Cole LA, Acuna E, Isozaki T, Palomaki GE, Bahado-Singh RO, Mahoney MO. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies. Prenat Diagn 1997; 17:1125-33. [PMID: 9467809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Recent articles by Cuckle et al., Canick et al., and Isozaki et al. have evaluated urine beta-core fragment as a screening test for Down syndrome in second-trimester pregnancies. They found over four-fold elevation of beta-core fragment levels in Down syndrome pregnancies, and between 62 and 88 per cent detection of this trisomy at a 5 per cent false-positive rate. Urine beta-core fragment may be a superior screening test for Down syndrome pregnancies. In the present study, urinary total oestriol has been evaluated as a marker to use in combination with beta-core fragment in screening for Down syndrome pregnancies. The two markers were evaluated separately in relation to the urine creatinine concentration. To amplify screening performance, we evaluated the ratio of beta-core fragment to total oestriol levels (creatinine-independent). beta-core fragment and total oestriol levels were determined (normalized to creatinine, ng/mg creatinine) in urine samples from 480 unaffected and 12 Down syndrome pregnancies, collected consecutively at a single prenatal diagnosis centre. The median beta-core fragment level in Down syndrome cases was 4.5 MOM. Fifty-eight per cent of Down syndrome cases had beta-core fragment levels exceeding the 95th centile of unaffected pregnancies. The median total oestriol level in Down syndrome cases was 0.33 MOM. Forty-two per cent of Down syndrome cases had total oestriol levels exceeding the 95th centile of unaffected pregnancies. We investigated the ratio of the two determinants (beta-core fragment, ng/ml divided by total oestriol, ng/ml) in our sample set. The median beta-core fragment:total oestriol ratio in Down syndrome cases was 13 MOM. Seventy-five per cent of Down syndrome cases had a ratio exceeding the 95th and the 99.5th centile of unaffected pregnancies. Total oestriol complements beta-core fragment in urine screening for Down syndrome pregnancies. A test measuring the ratio of the two urine determinants may be a significant improvement over current serum methods for detecting Down syndrome.
Collapse
Affiliation(s)
- L A Cole
- Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06520, USA.
| | | | | | | | | | | |
Collapse
|
38
|
Abstract
Human chorionic gonadotropin (hCG) free beta-subunit levels were determined in 709 control and 13 Down syndrome urine samples from the second trimester of pregnancy. Results were normalized to urine creatinine concentration and converted to multiples of the unaffected pregnancy medium (MOM). The concentration of free beta-subunit in Down syndrome cases was 3.9 MOM. Seven of 13 Down syndrome pregnancies (54 per cent) had free beta-subunit levels at or above the 95th centile of unaffected pregnancies. Urine free beta-subunit may potentially be useful as a screening test for Down syndrome.
Collapse
Affiliation(s)
- L A Cole
- Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06520, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Kellner LH, Canick JA, Palomaki GE, Neveux LM, Saller DN, Walker RP, Osathanondh R, Bombard AT. Levels of urinary beta-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome. Prenat Diagn 1997; 17:1135-41. [PMID: 9467810 DOI: 10.1002/(sici)1097-0223(199712)17:12<1135::aid-pd217>3.0.co;2-e] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Levels of beta-core fragment and total oestriol in second-trimester maternal urine samples were measured in 32 Down syndrome pregnancies and 206 control pregnancies. Beta-core fragment and total oestriol values were corrected for the urinary creatinine level and expressed as multiples of the control medians (MOM). In addition, the ratio of the beta-core fragment level to the total oestriol level, without creatinine correction, was calculated, and expressed as MOM values. The median beta-core fragment, total oestriol, and ratio levels in Down syndrome cases were 5.42, 0.64, and 9.32 MOM, respectively. In the Down syndrome pregnancies, 66 per cent of the beta-core fragment levels were above the 95th centile of control levels, while 22 per cent of the total oestriol levels were below the fifth centile of control levels. In combination with maternal age, measurement of beta-core fragment and total oestriol levels in Down syndrome pregnancy resulted in an 80 per cent detection rate at a 5 per cent false-positive rate. Use of the ratio resulted in a univariate detection rate of 72 per cent. In combination with maternal age, the ratio resulted in a detection rate of 81 per cent at a 5 per cent false-positive rate. Based on this unmatched study, the measurement of a ratio of beta-core fragment to total oestriol levels, without the need for creatinine correction, may be useful in screening for fetal Down syndrome in second-trimester urine.
Collapse
Affiliation(s)
- L H Kellner
- Department of Obstetrics and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Cole LA, Kellner LH, Isozaki T, Palomaki GE, Iles RK, Walker RP, Ozaki M, Canick JA. Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies. Prenat Diagn 1997; 17:607-14. [PMID: 9249860 DOI: 10.1002/(sici)1097-0223(199707)17:7<607::aid-pd118>3.0.co;2-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Urine is a new medium for Down syndrome testing. In an effort to determine the best type of human chorionic gonadotropin (hCG)-related immunoassay for urine testing, we examined 14 Down syndrome and 91 unaffected pregnancy urine samples with 12 established assays. The assays included (a) those that detect hCG beta-core fragment only; (b) those that detect beta-core fragment with less than 18 per cent free beta-subunit cross-reactivity; (c) that which equally detects free beta-subunit and beta-core fragment; and (d) those that detect hCG, free beta-subunit, or combinations thereof. The seven type a and b assays had the highest sensitivity for Down syndrome. The median MOM for Down syndrome was 5.93 (range 4.73-7.53). At a 10 per cent false-positive rate, the median observed detection rate was 93 per cent (range 79-100 per cent) and the median predicted detection rate was 85 per cent (range 69-96 per cent). The assays that did not mainly detect beta-core fragment (types c and d) had poorer screening performance. The median MOM for Down syndrome was 2.70 (range 2.16-3.63 MOM). At a 10 per cent false-positive rate, the median observed detection rate was 50 per cent (range 36-64 per cent) and the median predicted detection rate was 37 per cent (range 21-62 per cent). We infer that the assays that only detect beta-core fragment, or beta-core fragment with minor free beta-subunit cross-reactivity (types a and b), are the better urine-based tests for Down syndrome screening.
Collapse
Affiliation(s)
- L A Cole
- Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06520, USA.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Two recent publications by Cuckle et al., and one each by Canick et al. and Kellner et al., describe the use of urine beta-core fragment measurements as a screening test for Down syndrome pregnancies. Median levels of over 5.4 MOM were reported for cases of Down syndrome, with an over 72 per cent detection rate for a 5 per cent false-positive rate. Urine beta-core fragment was suggested as a superior screening test for Down syndrome pregnancies. These four studies were retrospectives, with samples from affected cases collected at different sites from those from normal cases. In the present study, prospective data were collected for 726 pregnancies over a 9-month period at a single medical centre. Fresh samples were assayed continuously, without knowledge of the karyotype. Urinary beta-core fragment levels in 709 unaffected samples continually declined from 12 to 24 weeks of pregnancy. A logarithmic fit was optimal for the median curve. The log standard deviation of unaffected samples was 0.368. All 13 Down syndrome cases had levels exceeding 1.0 MOM, with a median value of 4.1 MOM. Eight of 13 Down syndrome cases (62 per cent) had levels exceeding the 95th centile. Results have not been adjusted for maternal age, which may improve the detection rate. The results reported here, while less impressive than those reported previously, confirm the usefulness of urine beta-core fragment as a screening test for Down syndrome. Because of the prospective nature of this study, the 62 per cent sensitivity suggested here might be more representative of the true performance of urinary beta-core fragment in clinical practice than the higher rates observed in previous studies. Results for this single urine test are similar to those for triple screen and other serum combination tests. Single analyte urine beta-core fragment tests, or beta-core fragment combination protocols, may eventually replace serum analytes in screening for Down syndrome pregnancies.
Collapse
Affiliation(s)
- T Isozaki
- Department of Obstetrics and Gynaecology, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | |
Collapse
|
42
|
Abstract
OBJECTIVE Our goal was to determine the status of prenatal Down syndrome screening in the United States in 1995. STUDY DESIGN Information was sought via questionnaire from laboratories participating in external proficiency testing. RESULTS Services were provided to 2,498,000 women annually by 265 screening laboratories. All but 10 laboratories offered both open neural tube defect and Down syndrome screening. Twenty-one percent of Down syndrome interpretations were based on alpha-fetoprotein measurements alone; 79% also included other serum analytes. Sixty-six laboratories (26%) offered interpretations at 14 weeks' gestation or earlier. CONCLUSIONS Some laboratories extend serum screening too early in gestation for optimal neural tube defect interpretation. When 1995 was compared with 1992, more women were being screened, a higher proportion were receiving a Down syndrome interpretation, and more interpretations were based on multiple analytes. Laboratories should be encouraged to use some combination of multiple markers when screening for Down syndrome.
Collapse
Affiliation(s)
- G E Palomaki
- Foundation for Blood Research, Scarborough, ME 04070-0190, USA
| | | | | | | | | |
Collapse
|
43
|
Bradley LA, Canick JA, Palomaki GE, Haddow JE. Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 1997; 176:531-5. [PMID: 9077601 DOI: 10.1016/s0002-9378(97)70542-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Our purpose was to determine the prevalence of undetectably low second-trimester maternal serum unconjugated estriol levels and the association with increased perinatal morbidity or mortality in pregnancies at risk for placental sulfatase deficiency. STUDY DESIGN Nine centers in New England identified singleton pregnancies with undetectably low unconjugated estriol levels. Each unexplained case was matched with four controls; pregnancy outcome information was sought. RESULTS Among 130,295 pregnancies surveyed, undetectably low unconjugated estriol levels were identified in 167 (13/10,000). Explanations included fetal death (53), overestimated gestational age (50), nonpregnancy (12), and chromosome abnormalities (5). The 41 unexplained cases were compared with 163 matched controls. Male offspring were more frequent (85%) among cases than among controls (55%). Although rates of perinatal complications were not significantly different, primary cesarean sections occurred about twice as often among cases. No perinatal deaths occurred. CONCLUSIONS Neither severity of symptoms nor perinatal morbidity or mortality currently warrant routine interpretation of unexplained undetectably low unconjugated estriol levels as a marker for placental sulfatase deficiency.
Collapse
Affiliation(s)
- L A Bradley
- Foundation for Blood Research, Scarborough, ME 04070-0190, USA
| | | | | | | |
Collapse
|
44
|
Star J, Canick JA, Palomaki GE, Carpenter MW, Saller DN, Sung CJ, Tumber MB, Coustan DR. The relationship between second-trimester amniotic fluid insulin and glucose levels and subsequent gestational diabetes. Prenat Diagn 1997; 17:149-54. [PMID: 9061763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Associations between elevated amniotic fluid glucose and insulin levels in the second trimester and the subsequent development of gestational diabetes have been reported. We conducted a case-control study to determine which analyte best predicts future maternal glucose intolerance. Thirty-nine women diagnosed with gestational diabetes (criteria of Carpenter and Coustan, Am. J. Obstet. Gynecol., 144, 768, 1982) who had undergone genetic amniocentesis for advanced maternal age were matched with euglycaemic controls. Glucose and insulin concentrations were determined by analysis of stored amniotic fluid samples. No significant difference was detected between cases and controls for amniotic fluid glucose concentrations. Amniotic fluid insulin concentrations were significantly higher in cases (mean rank 4.44, P < 0.01, using matched rank analysis of variance, where 1 is the lowest and 6 is the highest rank). After conversion to multiples of the median, 20 per cent of women with subsequent gestational diabetes were found to have amniotic fluid glucose levels at or above the 90th centile, while 35 per cent of cases had similarly elevated amniotic fluid insulin levels. We conclude that second-trimester amniotic fluid insulin is a more sensitive predictor of impending glucose intolerance than amniotic fluid glucose, although neither is sufficiently powerful to use alone as a screening test.
Collapse
Affiliation(s)
- J Star
- Brown University School of Medicine, Women and Infants Hospital, Department of Obstetrics and Gynecology, Providence, RI 02905, USA
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Prenatal screening for Down's syndrome uses a risk estimate as the screening variable. Modifying the age-associated risk by measuring biochemical markers or fetal measurements requires more sophisticated mathematical techniques than calculating the observed estimates of the likelihood ratio. Frequently, the screening performance is reported on the same data used to generate the model. This can lead to an overestimate of the performance likely to be achievable in practice. In order to determine whether a proposed model for screening is better (or worse) than an established model, the two should be directly compared on a reasonably sized dataset of cases and controls that was not used to derive either of the models. At best, only marginal gains in screening performance can be expected using new or refined models for assigning Down's syndrome risk.
Collapse
Affiliation(s)
- G E Palomaki
- Foundation for Blood Research, Scarborough ME, 04074, USA
| |
Collapse
|
46
|
Abstract
This study examines the relationship between maternal weight and serum levels of alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotropin in a population of 47,585 women being provided with prenatal screening for Down's syndrome and open neural tube defects. The study population contains sufficient numbers of women at the extremes of weight to allow the determination that a reciprocal-linear equation more accurately describes the weight relationship for two of the three analytes than the currently used log-linear equations. The reciprocal-linear equations, while more appropriate, provide only a minimal advantage over the log-linear equations. A more important finding is that published weight equations may not be optimal for some screening programmes, due to differences in the mean weight of the populations being tested. Screening programmes are encouraged to calculate their own weight correction formulae, based on data from their own population, and to monitor the mean maternal weight to detect when modifications in the weight correction formulae might be indicated.
Collapse
Affiliation(s)
- L M Neveux
- Foundation for Blood Research, Scarborough, ME 04074, USA
| | | | | | | | | |
Collapse
|
47
|
|
48
|
Palomaki GE, Haddow JE. Nicked free beta-subunit and Down syndrome screening. Am J Obstet Gynecol 1996; 175:1075. [PMID: 8885779 DOI: 10.1016/s0002-9378(96)80056-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
49
|
Haddow JE, Palomaki GE, Knight GJ, Williams J, Chilmonczyk BA. Intervening to reduce environmental tobacco smoke exposure in infants. Pediatrics 1996; 98:513. [PMID: 8784385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
|
50
|
Palomaki GE, Haddow JE. Gestational dating and Down's syndrome screening. Ann Clin Biochem 1996; 33 ( Pt 4):359-61. [PMID: 8836400 DOI: 10.1177/000456329603300417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|